Compare AVAH & PVLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AVAH | PVLA |
|---|---|---|
| Founded | 1984 | 2015 |
| Country | United States | United States |
| Employees | N/A | 14 |
| Industry | Hospital/Nursing Management | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.6B |
| IPO Year | 2021 | N/A |
| Metric | AVAH | PVLA |
|---|---|---|
| Price | $7.36 | $114.64 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 15 |
| Target Price | $9.75 | ★ $171.87 |
| AVG Volume (30 Days) | ★ 1.4M | 188.2K |
| Earning Date | 05-14-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1850.00 | N/A |
| EPS | ★ 0.19 | N/A |
| Revenue | ★ $2,433,199,000.00 | N/A |
| Revenue This Year | $7.31 | N/A |
| Revenue Next Year | $5.59 | $104,350.18 |
| P/E Ratio | $38.66 | ★ N/A |
| Revenue Growth | ★ 20.19 | N/A |
| 52 Week Low | $3.73 | $20.20 |
| 52 Week High | $10.32 | $151.18 |
| Indicator | AVAH | PVLA |
|---|---|---|
| Relative Strength Index (RSI) | 57.30 | 44.62 |
| Support Level | $6.18 | $109.68 |
| Resistance Level | $7.52 | $114.69 |
| Average True Range (ATR) | 0.36 | 6.92 |
| MACD | 0.05 | -0.79 |
| Stochastic Oscillator | 54.10 | 43.13 |
Aveanna Healthcare Holdings Inc is a diversified home care platform that provides care to medically complex, high-cost patient populations. It directly addresses the pressing challenges facing the U.S. healthcare system by providing safe, high-quality care in the home. The firm provides its services through three segments: Private Duty Services (PDS); Home Health & Hospice (HHH); and Medical Solutions (MS). The Private Duty Services segment generates the majority of revenue, which includes private duty skilled nursing services, non-clinical and personal care services, and pediatric therapy services, and is principally reimbursed by Medicaid and Medicaid MCO.
Palvella Therapeutics Inc is a late clinical-stage biopharmaceutical company committed to serving individuals suffering from serious, rare genetic skin diseases without approved therapies. The Company's lead product candidate, QTORIN 3.9 percent rapamycin anhydrous gel (QTORIN rapamycin), is based on the Company's patented QTORIN platform. QTORIN rapamycin is in clinical development for two rare genetic skin disorders.